^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY1143269

    i
    Other names: BAY1143269, BAY 1143269, BAY-1143269
    Associations

    News

    Trials
    Company:
    Bayer
    Drug class:
    MKNK inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Preclinical anti-angiogenic and anti-cancer activities of BAY1143269 in glioblastoma via targeting oncogenic protein expression. (PubMed, Pharmacol Res Perspect)
    Immunoblotting analysis demonstrated significantly less phosphorylated-eIF4E (p-eIF4E), cluster of differentiation 31 (CD31) (microvascular endothelial cell marker), and VEGF in tumors from drug-treated mice. In summary, the inhibition of glioblastoma angiogenesis with BAY1143269 may provide an alternative approach for anti-glioblastoma therapy.
    Preclinical • Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • CDK7 (Cyclin Dependent Kinase 7) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    BAY1143269